|
|
| | AVP-13358 Basic information |
| Product Name: | AVP-13358 | | Synonyms: | N-2-Pyridinyl-2-[4-[(tricyclo[3.3.1.1(3,7)]dec-1-ylcarbonyl)amino]phenyl]-1H-benzimidazole-5-carboxamide;AVP-13358;2-[4-(Adamantan-1-ylcarboxamido)phenyl]-N-(2-pyridyl)-1H-benzimidazole-5-carboxamide;1H-Benzimidazole-6-carboxamide, N-2-pyridinyl-2-[4-[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)amino]phenyl]-;AVP13358,AVP 13358 | | CAS: | 459805-03-9 | | MF: | C30H29N5O2 | | MW: | 491.58356 | | EINECS: | | | Product Categories: | | | Mol File: | 459805-03-9.mol |  |
| | AVP-13358 Chemical Properties |
| Melting point | 328-330℃ | | density | 1.38 | | pka | 10.32±0.10(Predicted) |
| | AVP-13358 Usage And Synthesis |
| Uses | AVP-13358 is an orally active IgE inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC50 values of 8 and 3 nM for IgE inhibition in vivo and in vitro in BALB/c mice, respectively. AVP-13358 acts directly on T cells, inhibiting the production and release of IL-4, IL-5, and IL-13. It also targets other markers critical for the development of allergic responses, including the B cell IgE receptor (CD23) in human monocytes and the CD23 and IL-4 receptors in mouse B cells. AVP-13358 can be used in research related to anti-allergic responses[1]. | | IC 50 | IL-5; IL-13; IL-4 | | References | [1] Richards ML, et al. Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J Med Chem. 2004 Dec 16;47(26):6451-4. DOI:10.1021/jm049288j |
| | AVP-13358 Preparation Products And Raw materials |
|